Nonadherence to antipsychotics: The role of positive attitudes towards positive symptoms

European Neuropsychopharmacology

Volumn 24, Issue 11, 2014, Pages 1745-1752

  Moritz, Steffen ^a   Hünsche, Alexandra ^a,b   Lincoln, Tania M ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Adherence; Antipsychotics; Compliance; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CONFUSION; CONTROLLED STUDY; DELUSIONAL DISORDER; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PARANOIA; POSITIVE SYNDROME; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; TREATMENT REFUSAL; VISUAL DISORDER; ATTITUDE TO HEALTH; INTELLIGENCE TEST; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTELLIGENCE TESTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84918504501     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.09.008     Document Type: Article

References (50)

1. Alvarez-Jimenez M., Parker A.G., Hetrick S.E., McGorry P.D., Gleeson J.F. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr. Bull. 2011, 37:619-630.
2. Ascher-Svanum H., Nyhuis A.W., Stauffer V., Kinon B.J., Faries D.E., Phillips G.A., Schuh K., Awad A.G., Keefe R., Naber D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr. Med. Res. Opin. 2010, 26:2403-2410.
3. Byerly M.J., Nakonezny P.A., Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. N. Am. 2007, 30:437-452.
4. Chadwick P., Birchwood M. The omnipotence of voices. A cognitive approach to auditory hallucinations. Br. J. Psychiatry 1994, 164:190-201.
5. Chadwick P., Birchwood M. The omnipotence of voices. II: the Beliefs about Voices Questionnaire (BAVQ). Br. J. Psychiatry 1995, 166:773-776.
6. Copolov D.L., Mackinnon A., Trauer T. Correlates of the affective impact of auditory hallucinations in psychotic disorders. Schizophr. Bull. 2004, 30:163-171.
7. David A.S. Illness and insight. Br. J. Hosp. Med. 1992, 48:652-654.
8. Doroshow D.B. Performing a cure for schizophrenia: insulin coma therapy on the wards. J. Hist. Med. Allied Sci. 2007, 62:213-243.
9. Feldman R.P., Goodrich J.T. Psychosurgery: a historical overview. Neurosurgery 2001, 48:647-657.
10. Fioravanti M., Bianchi V., Cinti M.E. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry 2012, 12:64.
11. Gumley A.I., Gillan K., Morrison A.P., Schwannauer M. The development and validation of the Beliefs about Paranoia Scale (short form). Behav. Cogn. Psychother. 2011, 39:35-53.
12. Helbling J., Ajdacic-Gross V., Lauber C., Weyermann R., Burns T., Rossler W. Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population. BMC Psychiatry 2006, 6:42.
13. Hofmann S.G., Asnaani A., Vonk I.J., Sawyer A.T., Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cogn. Ther. Res. 2012, 36:427-440.
14. Howland R.H. Potential adverse effects of discontinuing psychotropic drugs. Part 3: antipsychotic, dopaminergic, and mood-stabilizing drugs. J. Psychosoc. Nurs. Ment. Health Serv. 2010, 48:11-14.
15. Hudson T.J., Owen R.R., Thrush C.R., Han X., Pyne J.M., Thapa P., Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry 2004, 65:211-216.
16. Jenner J.A., Rutten S., Beuckens J., Boonstra N., Sytema S. Positive and useful auditory vocal hallucinations: prevalence, characteristics, attributions, and implications for treatment. Acta. Psychiatr. Scand. 2008, 118:238-245.
17. Jones S.R., Fernyhough C., de-Wit L., Meins E. A message in the medium? Assessing the reliability of psychopathology e-questionnaires. Pers. Individ. Dif. 2008, 44:349-359.
18. Kemp R.A., David A.S. Insight and adherence to treatment in psychotic disorders. Br. J. Hosp. Med. 1995, 54:222-227.
19. Klapheck K., Nordmeyer S., Cronjager H., Naber D., Bock T. Subjective experience and meaning of psychoses: the German Subjective Sense in Psychosis Questionnaire (SUSE). Psychol. Med. 2012, 42:61-71.
20. Lambert M., Conus P., Cotton S., Robinson J., McGorry P.D., Schimmelmann B.G. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J. Clin. Psychopharmacol. 2010, 30:565-572.
21. Lambert M., Naber D. Current Schizophrenia 2012, Springer Healthcare, London.
22. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B [Multiple Choice Vocabulary Test] 1995, PERIMED-spitta, Balingen. 3rd ed.
23. Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011, 127:83-92.
24. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14:429-447.
25. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J. Clin. Psychiatry 2006, 67(Suppl. 5):S3-S8.
26. Lincoln T.M., Wilhelm K., Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr. Res. 2007, 96:232-245.
27. Matza L.S., Phillips G.A., Revicki D.A., Ascher-Svanum H., Malley K.G., Palsgrove A.C., Faries D.E., Stauffer V., Kinon B.J., Awad A.G., Keefe R.S., Naber D. Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Prefer. Adher. 2012, 6:521-532.
28. Miller B.J. A review of second-generation antipsychotic discontinuation in first-episode psychosis. J. Psychiatr. Pract. 2008, 14:289-300.
29. Miller L.J., O'Connor E., DiPasquale T. Patients' attitudes toward hallucinations. Am. J. Psychiatry 1993, 150:584-588.
30. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta. Psychiatr. Scand. 2006, 114:3-13.
31. Moritz S., Favrod J., Andreou C., Morrison A.P., Bohn F., Veckenstedt R., Tonn P., Karow A. Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis. Schizophr. Bull. 2013, 39:917-922.
32. Moritz S., Peters M.J.V., Karow A., Deljkovic A., Tonn P., Naber D. Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients. Ment. Illn. 2009, 1:4-9.
33. Moritz S., Rietschel L., Veckenstedt R., Bohn F., Schneider B.C., Lincoln T.M., Karow A. The other side of "madness": frequencies of positive and ambivalent attitudes towards prominent positive symptoms in psychosis. Psychosis 2014, (in press).
34. Moritz S., Van Quaquebeke N., Lincoln T.M., Kother U., Andreou C. Can we trust the internet to measure psychotic symptoms?. Schizophr. Res. Treat. 2013, 2013:457010.
35. Morrison A.P., Turkington D., Wardle M., Spencer H., Barratt S., Dudley R., Brabban A., Hutton P. A preliminary exploration of predictors of outcome and cognitive mechanisms of change in cognitive behaviour therapy for psychosis in people not taking antipsychotic medication. Beh. Res. Ther. 2012, 50:163-167.
36. Morrison A.P., Gumley A.I., Schwannauer M., Campbel M., Gleeson A., Griffin E., Gillan K.B. The Beliefs about Paranoia Scale: preliminary validation of a metacognitive approach to conceptualizing paranoia. Behav. Cogn. Psychother. 2005, 33:153-164.
37. Morrison A.P., Nothard S., Bowe S.E., Wells A. Interpretations of voices in patients with hallucinations and non-patient controls: a comparison and predictors of distress in patients. Behav. Res. Ther. 2004, 42:1315-1323.
38. Quach P.L., Mors O., Christensen T.O., Krarup G., Jorgensen P., Bertelsen M., Jeppesen P., Petersen L., Thorup A., Nordentoft M. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv. Psychiatry 2009, 3:66-74.
39. Schimmelmann B.G., Paulus S., Schacht M., Tilgner C., Schulte-Markwort M., Lambert M. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J. Child. Adolesc. Psychopharmacol. 2005, 15:249-258.
40. Stefanis N.C., Hanssen M., Smirnis N.K., Avramopoulos D.A., Evdokimidis I.K., Stefanis C.N., Verdoux H., Van Os J. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol. Med. 2002, 32:347-358.
41. Sundag S. Viel Feind - viel Ehr? Eine Untersuchung zum Zusammenhang von Selbstwert und Paranoia bei Schizophrenie [the more enemy, the more honor? An investigation into the relationship between self-esteem and paranoia in schizophrenia] 2012, University of Hamburg, Hamburg, Germany.
42. Tranulis C., Goff D., Henderson D.C., Freudenreich O. Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatr. Serv. 2011, 62:888-892.
43. Velligan D.I., Lam Y.W., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L., Miller A.L. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr. Bull. 2006, 32:724-742.
44. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):S1-S46.
45. Wiesjahn M., Jung E., Lamster F., Rief W., Lincoln T.M. Explaining attitudes and adherence to antipsychotic medication: The development of a process model. Schizophrenia Res. Treat. 2014, 11.
46. Wießner B., Felber W. Untersuchung zur Übereinstimmung zweier intelligenzdiagnostischer Testverfahren (HAWIE und MWT-B) an einer Stichprobe psychopathologisch auffälliger Patienten [Study of the agreement of two intelligence-diagnostic test methods on the basis of a random test carried out in psychopathologically conspicuous patients]. Psychiatr. Neurol. Med. Psychol. 1981, 33:744-748.
47. Woo T.U.W., Canuso C.M., Wojcik J.D., Brunette M.F., Green A.I. Treatment of schizophrenia. Textbook of Psychopharmacology 2009, American Psychiatric Publishing, Arlington, VA. 4th ed. A.F. Schatzberg, C.R. Nemeroff (Eds.).
48. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168:472-485.
49. Wykes T., Steel C., Everitt B., Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 2008, 34:523-537.
50. Ye W., Ascher-Svanum H., Tanji Y., Flynn J.A., Takahashi M. Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. Patient Prefer. Adher. 2011, 5:611-617.